Decreased mRNA expression of transcription factor forkhead box F2 is an indicator of poor prognosis in patients with resected esophageal squamous cell carcinoma

Zheng,Yu‑Zhen; Wen,Jing; Cao,Xun; Yang,Hong; Luo,Kong‑Jia; Liu,Qian‑Wen; Huang,Qing‑Yuan; Chen,Jun‑Ying; Fu,Jian‑Hua

doi:10.3892/mco.2015.511

Decreased mRNA expression of transcription factor forkhead box F2 is an indicator of poor prognosis in patients with resected esophageal squamous cell carcinoma

Authors:
- Yu‑Zhen Zheng
- Jing Wen
- Xun Cao
- Hong Yang
- Kong‑Jia Luo
- Qian‑Wen Liu
- Qing‑Yuan Huang
- Jun‑Ying Chen
- Jian‑Hua Fu
View Affiliations

Affiliations: Department of Thoracic Oncology, Sun Yat‑sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China, Guangdong Esophageal Cancer Institute, Guangzhou, Guangdong 510060, P.R. China
Published online on: February 16, 2015 https://doi.org/10.3892/mco.2015.511
Pages: 713-719

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The transcription factor forkhead box f2 (FOXF2) is an evolutionarily conserved DNA‑binding protein involved in embryogenesis and metabolism. Although recent studies prove that FOXF2 is a tumor suppressor in various human cancers, the role of FOXF2 in esophageal squamous cell carcinoma (ESCC) remains unknown. Therefore, samples were collected from 188 ESCC patients, including 33 pairs of tumor and non‑tumor tissues, and FOXF2 mRNA expression was investigated by quantitative polymerase chain reaction. The results demonstrated that FOXF2 mRNA is downregulated in tumor tissues compared to paired non‑tumor tissues (P=0.048). The receiver operating characteristic curve analysis indicated 1.2 as a cut‑off point and, thus, 125 and 63 tumors were classified as low- and high‑level FOXF2 mRNA expression, respectively. We observed that low‑level FOXF2 mRNA expression in the tumors was associated with a higher frequency of lymph node metastasis (P=0.044), an effect further suggested by the multivariate logistic regression analysis (P=0.060). According to the univariate Cox analysis, patients harboring tumors with low‑level FOXF2 mRNA expression had a significantly increased mortality risk compared to those with high‑level expression (hazard ratio=1.700, 95% confidence interval, 1.077‑2.681), with 5‑year survival rates of 41.1 and 61.9%, respectively. This negative prognostic effect of low‑level FOXF2 mRNA expression was further validated in the multivariate Cox analysis (P=0.021). The subgroup analysis demonstrated that the effect of FOX2 mRNA expression was limited to male patients and those with advanced‑stage disease. Taken together, these findings suggest that FOXF2 may be an anti‑oncogene for ESCC and decreased FOXF2 mRNA expression is associated with a poor prognosis in patients with ESCC.

View Figures

View References

1	Rice TW, Rusch VW, Apperson-Hansen C, et al: Worldwide esophageal cancer collaboration. Dis Esophagus. 22:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
2	Allum WH, Stenning SP, Bancewicz J, Clark PI and Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 27:5062–5067. 2009. View Article : Google Scholar : PubMed/NCBI
3	Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. Springer; Chicago: pp. 67–72. 2010
4	Carlsson P and Mahlapuu M: Forkhead transcription factors: Key players in development and metabolism. Dev Biol. 250:1–23. 2002. View Article : Google Scholar : PubMed/NCBI
5	Katoh M and Katoh M: Human FOX gene family (Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
6	Wang T, Tamakoshi T, Uezato T, Shu F, Kanzaki-Kato N, Fu Y, Koseki H, Yoshida N, Sugiyama T and Miura N: Forkhead transcription factor FoxF2 (LUN)-deficient mice exhibit abnormal development of secondary palate. Dev Biol. 259:83–94. 2003. View Article : Google Scholar : PubMed/NCBI
7	Ormestad M, Astorga J, Landgren H, Wang T, Johansson BR, Miura N and Carlsson P: Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development. 133:833–843. 2006. View Article : Google Scholar : PubMed/NCBI
8	Jochumsen U, Werner R, Miura N, Richter-Unruh A, Hiort O and Holterhus PM: Mutation analysis of FOXF2 in patients with disorders of sex development (DSD) in combination with cleft palate. Sex Dev. 2:302–308. 2008. View Article : Google Scholar : PubMed/NCBI
9	Yu L, Wynn J, Ma L, et al: De novo copy number variants are associated with congenital diaphragmatic hernia. J Med Genet. 49:650–659. 2012. View Article : Google Scholar : PubMed/NCBI
10	Westergren R, Nilsson D, Heglind M, Arani Z, Grände M, Cederberg A, Ahrén B and Enerbäck S: Overexpression of Foxf2 in adipose tissue is associated with lower levels of IRS1 and decreased glucose uptake in vivo. Am J Physiol Endocrinol Metab. 298:E548–E554. 2010. View Article : Google Scholar : PubMed/NCBI
11	Aitola M, Carlsson P, Mahlapuu M, Enerbäck S and Pelto-Huikko M: Forkhead transcription factor FoxF2 is expressed in mesodermal tissues involved in epithelio-mesenchymal interactions. Dev Dyn. 218:136–149. 2000. View Article : Google Scholar : PubMed/NCBI
12	Nik AM, Reyahi A, Pontén F and Carlsson P: Foxf2 in intestinal fibroblasts reduces numbers of Lgr5⁺ stem cells and adenoma formation by inhibiting Wnt signaling. Gastroenterology. 144:1001–1011. 2013. View Article : Google Scholar : PubMed/NCBI
13	van den Brink GR and Rubin DC: Foxf2: A mesenchymal regulator of intestinal adenoma development. Gastroenterology. 144:873–876. 2013. View Article : Google Scholar : PubMed/NCBI
14	Kong PZ, Yang F, Li L, Li XQ and Feng YM: Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor. PLoS ONE. 8:e615912013. View Article : Google Scholar : PubMed/NCBI
15	Hirata H, Ueno K, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS ONE. 8:e555022013. View Article : Google Scholar : PubMed/NCBI
16	Sachdeva M, Mito JK, Lee CL, et al: MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest. 124:4305–4319. 2014. View Article : Google Scholar : PubMed/NCBI
17	Lei R, Tang J, Zhuang X, et al: Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene. 33:1287–1296. 2014. View Article : Google Scholar : PubMed/NCBI
18	van der Heul-Nieuwenhuijsen L, Dits NF and Jenster G: Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 103:1574–1580. 2009. View Article : Google Scholar : PubMed/NCBI
19	van der Heul-Nieuwenhuijsen L, Dits N, Van Ijcken W, de Lange D and Jenster G: The FOXF2 pathway in the human prostate stroma. Prostate. 69:1538–1547. 2009. View Article : Google Scholar : PubMed/NCBI
20	Yang MH, Yu J, Jiang DM, Li WL, Wang S and Ding YQ: microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis. J Transl Med. 12:1092014. View Article : Google Scholar : PubMed/NCBI
21	Tang T, Wong HK, Gu W, Yu MY, To KF, Wang CC, Wong YF, Cheung TH, Chung TK and Choy KW: MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol. 129:199–208. 2013. View Article : Google Scholar : PubMed/NCBI
22	Ning FL, Wang F, Li ML, Yu ZS, Hao YZ and Chen SS: MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol. 9:1432014. View Article : Google Scholar : PubMed/NCBI
23	Gu ZD, Li JY, Li M, Gu J, Shi XT, Ke Y and Chen KN: Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol. 100:1835–1843. 2005. View Article : Google Scholar : PubMed/NCBI
24	Murray GI, Duncan ME, O'Neil P, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 2:461–462. 1996. View Article : Google Scholar : PubMed/NCBI
25	Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ and Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2 and prognosis. Clin Cancer Res. 10:7621–7628. 2004. View Article : Google Scholar : PubMed/NCBI
26	Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagström J and Haglund C: MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 31:149–155. 2010. View Article : Google Scholar : PubMed/NCBI
27	Jiang H, Li Q, He C, et al: Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer. Am J Cancer Res. 4:537–544. 2014.PubMed/NCBI
28	Dey N, Barwick BG, Moreno CS, et al: Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer. 13:5372013. View Article : Google Scholar : PubMed/NCBI
29	Yamamoto H, Oue N, Sato A, Hasegawa Y, Yamamoto H, Matsubara A, Yasui W and Kikuchi A: Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene. 29:2036–2046. 2010. View Article : Google Scholar : PubMed/NCBI
30	Uhm JE, Park YH, Yi SY, et al: Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer. 124:1457–1462. 2009. View Article : Google Scholar : PubMed/NCBI